Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

finance.yahoo.com/news/acadia-pharmaceuticals-price-target-raised-173632511.html

In This Article:
Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as consistent with its expectations for Nuplazid intellectual property…

This story appeared on finance.yahoo.com, 2025-05-17 17:36:32.
The Entire Business World on a Single Page. Free to Use →